Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Graft Versus Host Disease (GVHD) Market

Graft Versus Host Disease (GVHD) Market Share

  • Report ID: GMI8768
  • Published Date: Mar 2024
  • Report Format: PDF
 Download Free Sample

Graft Versus Host Disease Market Share

The GVHD industry exhibited high competitiveness with several players vying for prominence. Key competitors are utilizing diverse GVHD treatment portfolios to sustain market dominance, while others are providing specialized therapies. Competition pivoted on factors such as product efficacy, safety, regulatory approvals, and pricing, advancing innovation and collaborative efforts among industry stakeholders to drive advancements in the field.
 

Graft Versus Host Disease Market Companies

Prominent players operating in the graft versus host disease industry are as mentioned below:

  • Astellas Pharma Inc.
  • Bristol Myers Squibb
  • ElsaLys Biotech SA
  • Incyte Corporation
  • Johnson & Johnson Services, Inc.
  • Kiadis Pharma
  • Mallinckrodt Pharmaceuticals
  • Merck & Co., Inc.
  • Mesoblast Ltd.
  • Neovii Pharmaceuticals AG
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Soligenix
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Graft versus host disease (GVHD) industry size was USD 2.5 billion in 2023 and is expected to record USD 5.1 billion by 2032, due to the increasing prevalence of hematological disorders and malignancies necessitating hematopoietic stem cell transplantation (HSCT).

The hospital pharmacies distribution channel segment recorded 48.4% revenue share in 2023 and is expected to reach USD 2.4 billion by end of 2032, due to their pivotal role in providing immediate access to specialized medications and therapies.

North America graft versus host disease industry size was anticipated to reach USD 2.1 billion by 2032, attributed to its robust healthcare infrastructure, growing R&D activities, and escalating transplant rates.

Some of the leading GVHD firms are Astellas Pharma Inc., Bristol Myers Squibb, ElsaLys Biotech SA, Incyte Corporation, Johnson & Johnson Services, Inc., Kiadis Pharma, Mallinckrodt Pharmaceuticals, Merck & Co., Inc., and Mesoblast Ltd.

Graft Versus Host Disease Market Scope

  • Graft Versus Host Disease Market Size
  • Graft Versus Host Disease Market Trends
  • Graft Versus Host Disease Market Analysis
  • Graft Versus Host Disease Market Share

    • Buy Now

    Premium Report Details

    • Base Year: 2023
    • Companies covered: 14
    • Tables & Figures: 292
    • Countries covered: 19
    • Pages: 160
     Download Free Sample
    ×
    Get a free sample of Graft Versus Host Disease Market
    Inquiry Before Buying
    Get special pricing options on this report
    Request Sectional Data
    Over 70% of our clients customize reports to fit their needs. Please tell us how you would like to customize yours below

    Your personal details will remain secure and confidential.